CAR T cells are patient-derived, genetically engineered immune cells. They are "living drugs" and constitute a milestone in ...

Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that ...

The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...

Researchers found that zeaxanthin, long associated with eye health, may also boost the body’s immune response against cancer.

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid ...

"Our collaboration with Miltenyi Bioindustry plays a key role as we scale our programs," said Dr. Bryan Kim, CEO of Verismo ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...